Identifying PIK3R1 mutations in 61.54% of patients further emphasizes the role of the PI3K/AKT/mTOR pathway in this cancer type, supporting the rationale for ongoing research into targeted therapies that inhibit this pathway. The gene discussed is AKT1; the disease is cancer.